news
FDA Commissioner finalists under White House review
Three finalists to lead the FDA are currently being reviewed by the White House. This decision is crucial as it will shape the agency's stance on everything from GLP-1 and psychedelics to supplement regulations, directly impacting consumer access and safety for health products.
Three finalists to lead the FDA are currently being reviewed by the White House. This decision is crucial as it will shape the agency's stance on everything from GLP-1 and psychedelics to supplement regulations, directly impacting consumer access and safety for health products.
The architecture take
The person who ends up running the FDA calls the shots on pretty much everything we put in or on our bodies, from prescription meds to supplements. This isn't just about big pharma — it's about what you can actually buy off the shelf, the claims brands can make, and how quickly new therapies (hello, GLP-1s and psychedelics) get approved or restricted. A hard-liner could slow everything down, making it harder to access new treatments, while a more lenient chief might open up the floodgates, creating both opportunity and potential chaos in the health and wellness market. Watch for signals on their prior stances on "innovative" vs. "established" medical pathways. The future of your medicine cabinet and your nervous system hinges on this pick.